RDF/XMLNTriplesTurtleShow queryShare
SubjectPredicateObject
http://purl.uniprot.org/citations/24889609http://www.w3.org/1999/02/22-rdf-syntax-ns#typehttp://purl.uniprot.org/core/Journal_Citation
http://purl.uniprot.org/citations/24889609http://www.w3.org/2000/01/rdf-schema#comment"The adverse metabolic effects of prescribed and endogenous glucocorticoid (GC) excess, Cushing syndrome, create a significant health burden. We found that tissue regeneration of GCs by 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), rather than circulating delivery, is critical to developing the phenotype of GC excess; 11β-HSD1 KO mice with circulating GC excess are protected from the glucose intolerance, hyperinsulinemia, hepatic steatosis, adiposity, hypertension, myopathy, and dermal atrophy of Cushing syndrome. Whereas liver-specific 11β-HSD1 KO mice developed a full Cushingoid phenotype, adipose-specific 11β-HSD1 KO mice were protected from hepatic steatosis and circulating fatty acid excess. These data challenge our current view of GC action, demonstrating 11β-HSD1, particularly in adipose tissue, is key to the development of the adverse metabolic profile associated with circulating GC excess, offering 11β-HSD1 inhibition as a previously unidentified approach to treat Cushing syndrome."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.org/dc/terms/identifier"doi:10.1073/pnas.1323681111"xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Stewart P.M."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Bujalska I.J."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Lavery G.G."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Tomlinson J.W."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Gathercole L.L."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Hassan-Smith Z.K."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Morgan S.A."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"McCabe E.L."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/author"Larner D.P."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/date"2014"xsd:gYear
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/name"Proc Natl Acad Sci U S A"xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/pages"E2482-91"xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/title"11beta-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess."xsd:string
http://purl.uniprot.org/citations/24889609http://purl.uniprot.org/core/volume"111"xsd:string
http://purl.uniprot.org/citations/24889609http://www.w3.org/2004/02/skos/core#exactMatchhttp://purl.uniprot.org/pubmed/24889609
http://purl.uniprot.org/citations/24889609http://xmlns.com/foaf/0.1/primaryTopicOfhttps://pubmed.ncbi.nlm.nih.gov/24889609
http://purl.uniprot.org/uniprot/#_F2Z3U6-mappedCitation-24889609http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24889609
http://purl.uniprot.org/uniprot/#_F6TSI8-mappedCitation-24889609http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24889609
http://purl.uniprot.org/uniprot/#_P50172-mappedCitation-24889609http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24889609
http://purl.uniprot.org/uniprot/#_Q4JHD9-mappedCitation-24889609http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24889609
http://purl.uniprot.org/uniprot/#_Q3TJI8-mappedCitation-24889609http://www.w3.org/1999/02/22-rdf-syntax-ns#objecthttp://purl.uniprot.org/citations/24889609
http://purl.uniprot.org/uniprot/F6TSI8http://purl.uniprot.org/core/mappedCitationhttp://purl.uniprot.org/citations/24889609